Mitchell Chan - 06 Jan 2026 Form 4 Insider Report for REGENXBIO Inc. (RGNX)

Reporting relationship: Chief Financial Officer
Issuer ticker: RGNX
Reported as of: 06 Jan 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 08 Jan 2026, 16:33:39 UTC
Prior SEC filing: 03 Sep 2025
Next SEC filing: 31 Mar 2026
Source filing: View source filing
Reporting owner signature: /s/ Patrick J. Christmas as attorney-in-fact

Key filing fact

Mitchell Chan filed Form 4 for REGENXBIO Inc. (RGNX) on 08 Jan 2026.

Key facts

This page summarizes Mitchell Chan's Form 4 filing for REGENXBIO Inc. (RGNX).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 08 Jan 2026, 16:33.

Change

Previous filing in this sequence was filed on 03 Sep 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001789335 Primary reporting owner

Chan Mitchell

Relationship: Chief Financial Officer
Address: C/O REGENXBIO INC., 9804 MEDICAL CENTER DRIVE, ROCKVILLE
Signature: /s/ Patrick J. Christmas as attorney-in-fact
Signature date: 08 Jan 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

RGNX transaction

Common Stock

Award

Transaction value: $0
Shares: +73,749
Change %: +137%
Price: $0.000000
Shares after: 127,717
Date: 06 Jan 2026
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

RGNX transaction Derivative

Stock Options (Right to buy)

Award

Transaction value: $0
Shares: +39,650
Change %
Price: $0.000000
Shares after: 39,650
Date: 06 Jan 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 39,650
Exercise price: $14.18
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Represents shares of common stock underlying a time-based restricted stock unit award (RSU). 25% of the shares subject to this RSU will vest on each of January 6, 2027, January 6, 2028, January 6, 2029 and January 6, 2030 while the recipient provides continuous service to the Issuer.

Footnote F2

25% of the shares subject to this option shall vest after 12 months of continuous service with the Issuer. The balance will vest in equal monthly installments over the 36 months following January 6, 2027 while the optionee provides continuous service to the Issuer.